WO2006119458A1 - Gene therapy for neurometabolic disorders - Google Patents
Gene therapy for neurometabolic disorders Download PDFInfo
- Publication number
- WO2006119458A1 WO2006119458A1 PCT/US2006/017242 US2006017242W WO2006119458A1 WO 2006119458 A1 WO2006119458 A1 WO 2006119458A1 US 2006017242 W US2006017242 W US 2006017242W WO 2006119458 A1 WO2006119458 A1 WO 2006119458A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- aav2
- site
- asm
- aav vector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Definitions
- LSD liver-specific enzymopathy
- ERT enzyme replacement therapy
- Gaucher type 1 patients have only visceral disease and respond favorably to ERT with recombinant glucocerebrosidase (Cerezyme®, Genzyme Corp.).
- AD Alzheimer's disease
- CNS central nervous system
- a ⁇ amyloid ⁇ -peptide
- Gene therapy is an emerging treatment modality for disorders affecting the CNS, including LSDs and Alzheimer's disease. In this approach, restoration of the normal metabolic pathway and reversal of pathology occurs by transducing affected cells with a vector carrying a healthy version or a modified version of the gene.
- CNS gene therapy has been facilitated by the development of viral vectors capable of effectively infecting post-mitotic neurons. For a review of viral vectors for gene delivery to the CNS, see Davidson et al. (2003) Nature Rev., 4:353-364.
- Adeno-associated virus (AAV) vectors are considered optimal for CNS gene therapy because they have a favorable toxicity and immunogenicity profile, are able to transduce neuronal cells, and are able to mediate long-term expression in the CNS (Kaplitt et al. (1994) Nat. Genet., 8:148-154; Bartlett et al. (1998) Hum. Gene Ther., 9:1181-1186; and Passini et al. (2002) J. Neurosci., 22:6437-6446).
- AAV Adeno-associated virus
- a therapeutic transgene product e.g., an enzyme
- transduced cells can be secreted by transduced cells and subsequently taken up by other cells, in which it then alleviates pathology.
- This process is known as cross-correction (Neufeld et al. (1970) Science, 169:141-146).
- pathology such as storage pathology in the context of LSD
- the correction of pathology is typically confined to the immediate vicinity of the injection site because of limited parenchymal diffusion of the injected vector and the secreted transgene product (Taylor et al. (1997) Nat. Med., 3:771-774; Skorupa et al. (1999) Exp. Neurol., 160:17-27).
- neuropathology affecting multiple brain regions requires widespread vector delivery, using multiple spatially distributed injections, especially in a large brain such as human. This significantly increases the risk of brain damage.
- some regions of the brain may be difficult to access surgically.
- other modes of vector transport within the CNS, besides diffusion, would be beneficial.
- viruses When administered at axonal endings, some viruses are internalized and transported retrogradely along the axon to the nucleus. Neurons in one brain region are interconnected by axons to distal brain regions thereby providing a transport system for vector delivery.
- adenovirus, HSV, and pseudo-rabies virus have utilized trafficking properties of these viruses to deliver genes to distal structures within the brain (Soudas et al. (2001) FASEB J., 15:2283-2285; Breakefield et al. (1991) New Biol., 3:203-218; and deFalco et al. (2001) Science, 291:2608-2613).
- AAV2 AAV serotype 2
- AAV2 serotype 2 Several groups have reported that the transduction of the brain by AAV serotype 2 (AAV2) is limited to the intracranial injection site (Kaplitt et al. (1994) Nat. Genet., 8:148-154; Passini et al. (2002) J. NeuroscL, 22:6437-6446; and Chamberlin et al. (1998) Brain Res., 793:169-175).
- AAV2 AAV serotype 2
- the invention provides methods and compositions for treating or preventing metabolic disorders, such as lysosomal storage diseases (LSD) or abnormal cholesterol storage function that are characterized by or associated with a risk of diminution of CNS function.
- metabolic disorders such as lysosomal storage diseases (LSD) or abnormal cholesterol storage function that are characterized by or associated with a risk of diminution of CNS function.
- LSD lysosomal storage diseases
- abnormal cholesterol storage function that are characterized by or associated with a risk of diminution of CNS function.
- the invention provides methods and compositions for treating or preventing disorders affecting the central nervous system (CNS) 1 such as Alzheimer's disease that are characterized by or associated with a risk of diminution of CNS function.
- CNS central nervous system
- the invention further provides methods for minimally invasive targeted delivery of a transgene to select regions in the brain of an affected subject.
- Acid sphingomyelinase (ASM) knockout mice a model of Niemann-Pick Type A disease, were administered an AAV2 vector carrying the human ASM gene (AAV-ASM) by a single intracranial injection into one hemisphere of the brain.
- AAV-ASM AAV2 vector carrying the human ASM gene
- the present invention is based, in part, on the discovery and demonstration that the injection of high titer AAV-ASM into the diseased brain results in AAV-ASM expression within multiple distal sites in a pattern consistent , with the topographical organization of the projection neurons that innervate the injection site.
- the invention is further based, in part, on the discovery and demonstration of extensive correction of lysosomal storage pathology at the injection site and distal sites to which AAV-ASM was transported and where ASM was expressed.
- the invention provides a method to correct cholesterol storage pathology and initiate functional recovery in the ASMKO mouse after unilateral or alternatively, bilateral injection within the deep cerebellar nuclei.
- transgene is devivered in a recombinant AAV vector selected from the group consisting of AAV2/1, AAV2/2, AAV2/5, AAV2/7 and AAV2/8 serotype.
- a recombinant AAV vector selected from the group consisting of AAV2/1, AAV2/2, AAV2/5, AAV2/7 and AAV2/8 serotype.
- the recombinant vectors encoded functional human ASM protein in a mouse model.
- the present invention provides methods for treating neurometabolic disorders in mammals.
- the populations treated by the methods of the invention include, but are not limited to, patients having or at risk for developing a LSD, such as disorders listed in Table 1 , particularly, if such disease affects the CNS.
- the disease is Niemann-Pick A disease and/or the secondary cholesterol storage pathology commonly associated with NPA.
- the disclosed methods include administering to the CNS of an afflicted subject an AAV viral vector carrying a transgene encoding a therapeutic product and allowing the transgene to be expressed within the CNS distally from the administration site at a therapeutic level.
- the vector may comprise a polynucleotide encoding for a biologically active molecule effective to treat the CNS disorder.
- biologically active molecules may comprise peptides including but not limited to native or mutated versions of full- length proteins, native or mutated versions of protein fragments, synthetic polypeptides, antibodies, and antibody fragments such as Fab' molecules.
- Biologically active molecules may also comprise nucleotides including single- stranded or double-stranded DNA polynucleotides and single-stranded or double- stranded RNA polynucleotides.
- the administration is accomplished by direct intraparenchymal injection of a high titer AAV vector solution into the diseased brain. Thereafter the transgene is expressed distally, contralateral ⁇ or ipsilaterally, to the administration site at a therapeutic level at least 2, 3, 5, 8, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mm from the administration site.
- the invention also provides a method of delivering a recombinant AAV genome to the nucleus of a disease-compromised neuron in vivo.
- the cellular pathology exhibited by the neuron is that of a lysosomal storage disease such as disorders listed in Table 1.
- the disease is Niemann-Pick A disease.
- the cellular pathology exhibited is that of Alzheimer's disease.
- the method of delivering a recombinant AAV genome to the nucleus of a disease-compromised neuron comprises contacting an axonal ending of the disease-compromised neuron with a composition comprising an AAV viral particle comprising the recombinant AAV genome and allowing the viral particle to be endocytosed and retrogradely transported intracellular ⁇ along the axon to the nucleus of the neuron.
- the concentration of the vector in the composition is at least: (a) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (*10 12 gp/ml); (b) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 ( ⁇ 10 9 tu/ml); or (c) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 ( ⁇ 10 10 iu/ml).
- the neuron is a projection neuron and/or the distance of the axonal ending to the nucleus of the neuron is at least 2, 3, 5, 8, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mm.
- This invention provides methods and compositions to deliver a transgene to the spinal cord and/ or the brainstem region of a subject by administering a recombinant neurotropic viral vector containing the transgene to at least one region of the deep cerebellar nuclei (DCN) region of the subject's brain.
- the viral delivery is under conditions that favor expression of the transgene in the spinal cord and/ or the brainstem region.
- the disease is Niemann-Pick A disease.
- the cellular pathology exhibited is that of Alzheimer's disease.
- the invention provides methods and compositions to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene to the motor cortex region of the subject's brain.
- the delivery of the viral vector is under conditions that favor expression of the transgene in the spinal cord.
- Viral vectors administered to the motor cortex region are internalized by motor neurons via their cell body region and the transgene is expressed. The expressed transgene may then undergo anterograde transport to the axon terminal portion of the motor neuron, which is present in the spinal cord. Due to the nature of the motor cortex, viral vectors administered to this region of the brain may also be internalized by axon terminals of motor neurons.
- the viral vector also may undergo retrograde transport along the motor neuron's axon and be expressed in the cell body of the motor neuron.
- the disease is Niemann-Pick A disease.
- the cellular pathology exhibited is that of Alzheimer's disease.
- the invention provides a method of delivering a therapeutic transgene product to a target cell of the CNS, which is a neuron or a glial cell, in a mammal afflicted with a neurometabolic disorder, e.g., an LSD that affects the CNS.
- the method includes contacting an axonal ending of a neuron with a composition containing an AAV vector carrying at least a part of a gene encoding a therapeutic transgene product, allowing the viral particle to be endocytosed and retrogradely transported intracellular ⁇ along the axon to the nucleus of the neuron; allowing the therapeutic transgene product to be expressed and secreted by the neuron, and allowing the target cell to uptake the therapeutic transgene product, wherein the therapeutic transgene product thereby alleviates pathology in the target cell.
- the concentration of the vector in the composition is at least: (a) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (x10 12 gp/ml); (b) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (x10 9 tu/ml); or (c) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (x10 10 iu/ml).
- the therapeutic transgene encodes a biologically active molecule, expression of which in the CNS results in at least partial correction of neuropathology.
- the therapeutic transgene product is a lysosomal hydrolase.
- the lysosomal hydrolase is ASM.
- the therapeutic transgene is a metalloendopeptidase, e.g., neprilysin.
- Figure 1 A depicts a representation of a cross-section of the ASMKO mouse brain, at 5 or 15 weeks following a 2 ⁇ l injection of high titer (9.3 x 10 12 gp/ml) AAV-ASM into the hippocampus.
- the site of injection is shown by a vertical line;
- ASM mRNA expression, as detected by in situ hybridization, is represented the smaller circles;
- ASM protein expression, as detected by immunohistochemical staining, is represented by the larger shaded circles.
- the expression pattern resulted in an extensive area of reversal of pathology (represented by the light shading) in the hippocampus and cortical regions in both hemispheres of the brain.
- Figure 1 B depicts the axonal transport of AAV to distal regions of the mouse brain following a high titer AAV injection into the hippocampus as described for Figure 1A. Injection into the hippocampus (10) resulted in axonal transport of the viral vector via the intrahippocampal circuit to the contralateral hippocampus (20) and via the entorhinodentate circuit to the entorhinal cortex (30). The site of injection is shown by a vertical line.
- FIG. 1C is a schematic diagram showing the connections of the intrahippocampal and entorhinodentate circuits of the mouse brain.
- Injection into the hippocampus (10) results in infection and transduction of cell bodies located in the cornu ammonis area 3 (CA3) and in the dentate granule cell layer (G).
- CA3 cornu ammonis area 3
- G dentate granule cell layer
- a subset of the injected AAV vector infects the axonal endings of the projection neurons innervating the injection site, undergoes retrograde axonal transport, and delivers the transgene to the CA3 field (CA3) and hilus (H) in the contralateral part of the hippocampus (20), and ipsilaterally in the entorhinal cortex (30).
- CA3 field CA3
- H hilus
- Figure 2A depicts a representation of a cross-section of the ASMKO mouse brain, at 5 or 15 weeks following an intrahippocampal injection of high titer AAV-ASM as described in Figure 1A.
- ASM mRNA expression as detected by in situ hybridization, is represented by the smaller circles; and ASM protein expression, as detected by immunohistochemical staining, is represented by the larger shaded circles.
- the injection resulted in ASM mRNA and protein to be detected in the septum. This expression pattern resulted in an extensive area of reversal of pathology (represented by the light shading).
- Figure 2B depicts the axonal transport of AAV to distal regions of the mouse brain, following a high titer injection into the hippocampus as described in Figure 1A. Injection into the hippocampus (10) resulted in axonal transport of the viral vector via the septohippocampal circuit from the injection site (represented by a vertical line) to the septum (40).
- Figure 2C is a schematic diagram showing the connections of the septohippocampal circuit. Injection into the hippocampus resulted in transduction to cell bodies located in the CA3 field (11). In addition, a subset of the AAV vector infects the axonal endings of the projection neurons innervating the injection site, undergoes retrograde axonal transport, and delivers the transgene to the medial septum (40).
- Figure 3 depicts the axonal transport of AAV in the nigrostriatal circuit, following a high titer injection of AAV into the striatum (50) of the mouse brain.
- Axonal transport of AAV occurs from the injection site (represented by a vertical line) to the substantia nigra (60).
- Figure 4 depicts the axonal transport of AAV in the medullocerebellar circuit, following a high titer injection of AAV-ASM into the cerebellum (70) of the ASMKO mouse brain.
- Axonal transport of AAV2 occurs from the injection site (represented by a vertical line) to the medulla oblongata (80).
- Figure 5 depicts axonal transport of AAV in the intrahippocampal, nigrostriatal, and entorhinodentate circuits following high-titer injection of AAV7- ASM in the ispilateral hippocampus (10). Transduced cells were detected, as determined by in situ hybridization, along the entire rostral-caudal axis of the contralateral hippocampus (90), medial septum (40), and entorhinal cortex (100) after AAV7-ASM injection of the ipsilateral hippocampus (represented by a vertical line).
- Figures 6A through 6E show human ASM immunopositive staining in sagittal cerebellar sections following injection of different AAV serotype vectors [(A)2/1 , (B)2/2, (C)2/5, (D)2/7 and (E)2/8] encoding for human ASM into the deep cerebellar nuclei of ASMKO mice.
- Figures 7 A through 7E demonstrate hASM transport to the spinal cord from the deep cerebellar nuclei.
- mice treated with AAV2/2-ASM, AAV2/5 -ASM, AAV2/7-ASM & AAV2/8-ASM (A) hASM 10X magnification; (B) hASM 4OX magnification; (C) confocal hASM; (D) confocal ChAT; and (E) confocal hASM & ChAT.
- Figures 9A through G show calbindin immunopositive staining in sagittal cerebellar sections following injection of different AAV serotype vectors [(A)2/1 , (B)2/2, (C)2/5, (D)2/7 and (E)2/8] encoding for human ASM into the deep cerebellar nuclei of ASMKO mice.
- AAV-ASM treated mice performed significantly (p ⁇ .001) better than ASMKO AAV2/1- ⁇ gal treated mice.
- Performance of mice injected with AAV2/1-ASM were indistinguishable from wild type mice in both the accelerating and rocking tests.
- Figure 13A illustrates the connections between the deep cerebellar nuclei regions (medial, interposed, and lateral) and the spinal cord regions (cervical, thoracic, lumbar, and sacral).
- Figure 13B illustrates the connections between the deep cerebellar nuclei regions (medial, interposed, and lateral) and the brainstem regions (midbrain, pons, and medulla). The connections are represented by arrows, which start at the cell body region of a neuron and end at the axon terminal region of the neuron.
- the three regions of the DCN each have neurons with cell bodies that send axons that terminate in the cervical region of the spinal cord while the cervical region of the spinal cord has cell bodies that send axons that terminate in either the medial or interposed regions of the DCN.
- Figure 14 illustrates green fluorescent protein distribution in the brainstem, or upper motor neurons, following DCN delivery of AAV encoding for green fluorescent protein (GFP).
- GFP green fluorescent protein
- Figure 15 illustrates green fluorescent protein distribution in the spinal cord regions following DCN delivery of AAV encoding for green fluorescent protein (GFP).
- GFP green fluorescent protein
- Figure 16 shows GFP distribution within the mouse brain following bilateral delivery of a GFP expressing AAV1 vector to the deep cerebellar nuclei (DCN).
- DCN deep cerebellar nuclei
- GFP positive staining was also observed in the olfactory bulbs, cerebral cortex, thalamus, brainstem, cerebellar cortex and spinal cord. All of these areas either receive projections from and/or send projections to the DCN.
- transgene refers to a polynucleotide that is introduced into a cell of and is capable of being translated and/or expressed under appropriate conditions and confers a desired property to a cell into which it was introduced, or otherwise leads to a desired therapeutic outcome.
- gene particles refer to the number of virions containing the recombinant AAV DNA genome, regardless of infectivity or functionality.
- the number of genome particles in a particular vector preparation can be measured by procedures such as described in the Examples herein, or for example, in Clark et al. (1999) Hum. Gene Ther., 10:1031-1039; Veldwijk et al. (2002) MoI. Ther., 6:272-278.
- infection unit (iu), infectious particle
- replication unit replication unit
- infectious center assay also known as replication center assay
- transducing unit (tu) refers to the number of infectious recombinant AAV vector particles that result in the production of a functional transgene product as measured in functional assays such as described in Examples herein, or for example, in Xiao et al. (1997) Exp. Neurobiol., 144:113-124; or in Fisher et al. (1996) J. Virol., 70:520-532 (LFU assay).
- terapéutica refers to that amount of a compound that results in prevention or delay of onset or amelioration of symptoms of in a subject or an attainment of a desired biological outcome, such as correction of neuropathology, e.g., cellular pathology associated with a lysosomal storage disease such as that described herein or in Walkley (1998) Brain Pathol., 8:175-193.
- therapeutic correction refers to that degree of correction that results in prevention or delay of onset or amelioration of symptoms in a subject.
- the effective amount can be determined by methods well-known in the art and as described in the subsequent sections.
- ASMKO mice are an accepted model of types A and B Niemann-Pick disease (Horinouchi et al. (1995) Nat. Genetics, 10:288-293; Jin et al. (2002) J. Clin. Invest, 109:1183-1191; and Otterbach (1995) Cell, 81:1053-1061).
- Niemann-Pick disease is classified as a lysosomal storage disease and is an inherited neurometabolic disorder characterized by a genetic deficiency in acid sphingomyelinase (ASM; sphingomyelin cholinephosphohydrolase, EC 3.1.3.12).
- ASM protein results in the accumulation of sphingomyelin substrate within the lysosomes of neurons and glia throughout the brain. This leads to the formation of large numbers of distended lysosomes in the perikaryon, which are a hallmark feature and the primary cellular phenotype of type A NPD. The presence of distended lysosomes correlates with the loss of normal cellular function and a progressive neurodegenerative course that leads to death of the affected individual in early childhood (The Metabolic and Molecular Bases of Inherited Diseases, eds. Scriver et al., McGraw-Hill, New York, 2001, pp. 3589-3610).
- Sphingomyelin has strong affinity for cholesterol, which results in the sequestering of large amounts of cholesterol in the lysosomes of ASMKO mice and human patients (Leventhal et al. (2001) J. Biol. Chem., 276:44976-44983; Slotte (1997) Subcell. Biochem., 28:277-293; and Viana et Ia. (1990) J. Med.
- the present invention is based, in part, on the discovery and demonstration that an intrahippocampal injection of high titer AAV-ASM into the diseased brains of ASMKO mice results in expression of ASM mRNA and protein distally from the injection site in a pattern consistent with the topographical organization of the projection neurons that innervate the injection site.
- ASM mRNA and protein are also detected in several distal regions outside of the ipsilateral (injected) hippocampus, specifically, in the contralateral hippocampal dentate gyrus and CA3, and the medial septum and entorhinal cortex.
- the invention is further based, in part, on the discovery and demonstration of the extensive correction of lysosomal storage pathology at the distal sites thereby allowing a larger volume of correction via a smaller number of injection sites.
- the present invention provides methods for treating neurometabolic disorders in mammals.
- the populations treated by the methods of the invention include, but are not limited to, patients having or at risk for developing a neurometabolic disorder, e.g., a LSD, such as diseases listed in Table 1, particularly, if such a disease affects the CNS.
- a neurometabolic disorder e.g., a LSD
- the disease is type A Niemann-Pick disease.
- neurometabolic disorders may exclude Alzheimer's, Parkinson, Huntington, Tay Sachs, Lesch-Nyan, and Creutzfeldt-Jakob diseases.
- methods of the invention utilizing a metalloendopeptidase as a therapeutic transgene, are specifically useful to the treatment of Alzheimer's disease and amyloid-related disorders.
- the method of treating a neurometabolic disorder comprises administration of a high titer AAV vector carrying a therapeutic transgene so that the transgene product is expressed at a therapeutic level in a second site within the CNS distal to the first site.
- the viral titer of the composition is at least: (a) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 ( ⁇ 10 12 gp/ml); (b) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 ( ⁇ 10 9 tu/ml); or (c) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 ( ⁇ 10 10 iu/ml).
- the administration is accomplished by direct intraparenchymal injection of a high titer AAV vector solution into the diseased brain, thereafter the transgene is expressed distally, contralaterally or ipsilaterally, to the administration site at a therapeutic level at least 2, 3, 5, 8 ,10, 15, 20, 25, 30, 35, 40, 45, or 50 mm from the administration site.
- the distance between the first and the second sites is defined as the minimal distance region between the site of administration (first site) and the boundary of the detectable transduction of the distal site (second site) as measured using procedures known in the art or as described in the Examples, e.g., in situ hybridization.
- Some neurons in the CNS of larger mammals may span large distances by virtue of their axonal projections. For example, in humans, some axons may span a distance of 1000 mm or greater.
- AAV can be axonally transported along the entire length of the axon at such a distance to reach and transduce the parent cell body.
- a site of vector administration within the CNS is chosen based on the desired target region of neuropathology and the topology of brain circuits involved so long as an administration site and the target region have axonal connections.
- the target region can be defined, for example, using 3-D sterotaxic coordinates.
- the administration site is chosen so that at least 0.1 , 0.5, 1 , 5, or 10 % of the total amount of vector injected is delivered distally at the target region of at least 1, 200, 500, or 1000 mm 3 .
- An administration site may be localized in a region innervated by projection neurons connecting distal regions of the brain.
- the substantia nigra and bventral tegmental area send dense projections to the caudate and putamen (collectively known as the striatum).
- Neurons within the substantia nigra and ventral tegmentum can be targeted for transduction by retrograde transport of AAV following injection into the striatum.
- the hippocampus receives well-defined, predictable axonal projections from other regions of the brain.
- Other administration sites may be localized, for example, in the spinal cord, brainstem (medulla and pons), mesencephalon, cerebellum (including the deep cerebellar nuclei), diencephalon (thalamus, hypothalamus), telencephalon (corpus striatum, cerebral cortex, or, within the cortex, the occipital, temporal, parietal or frontal lobes), or combinations thereof.
- brainstem medulla and pons
- mesencephalon including the deep cerebellar nuclei
- diencephalon thalamus, hypothalamus
- telencephalon corpus striatum, cerebral cortex, or, within the cortex, the occipital, temporal, parietal or frontal lobes
- telencephalon corpus striatum, cerebral cortex, or, within the cortex, the occipital, temporal, parietal or frontal lobes
- entorhinal-hippocampus projections For example, most mammals, including humans and rodents, show a similar topographical organization of the entorhinal-hippocampus projections, with neurons in the lateral part of both the lateral and medial entorhinal cortex projecting to the dorsal part or septal pole of the hippocampus, whereas the projection to the ventral hippocampus originates primarily from neurons in medial parts of the entorhinal cortex (Principles of Neural Science, 4th ed., eds Kandel et al., McGraw-Hill, 1991; The Rat Nervous System, 2nd ed., ed. Paxinos, Academic Press, 1995).
- layer Il cells of the entorhinal cortex project to the dentate gyrus, and they terminate in the outer two-thirds of the molecular layer of the dentate gyrus.
- the axons from layer III cells project bilaterally to the cornu ammonis areas CA1 and CA3 of the hippocampus, terminating in the stratum lacunose molecular layer.
- the second (target) site can be located any region of the CNS, including the brain and the spinal cord, that contains a neurons that project to the first (administration) site.
- the second site is in a region of the CNS chosen from the substantia nigra, the medulla oblongata, or the spinal cord.
- the vector specifically to a particular region of the central nervous system, especially to a particular region of the brain, it may be administered by sterotaxic microinjection.
- sterotaxic microinjection For example, on the day of surgery, patients will have the sterotaxic frame base fixed in place (screwed into the skull).
- the brain with sterotaxic frame base (MRI-compatible with fiduciary markings) be imaged using high resolution MRI.
- the MRI images will then be transferred to a computer that runs stereotaxic software.
- a series of coronal, sagittal and axial images will be used to determine the target site of vector injection, and trajectory.
- the software directly translates the trajectory into 3-dimensional coordinates appropriate for the stereotaxic frame.
- Burr holes are drilled above the entry site and the stereotaxic apparatus localized with the needle implanted at the given depth.
- the vector in a pharmaceutically acceptable carrier will then be injected.
- the AAV vector is then administrated by direct injection to the primary target site and retrogradely transported to distal target sites via axons. Additional routes of administration may be used, e.g., superficial cortical application under direct visualization, or other non-stereotaxic application.
- the total volume of material to be administered, and the total number of vector particles to be administered, will be determined by those skilled in the art based upon known aspects of gene therapy. Therapeutic effectiveness and safety can be tested in an appropriate animal model. For example, a variety of well-characterized animal models exist for LSDs, e.g., as described herein or in Watson et al. (2001) Methods MoI. Med., 76:383-403; or Jeyakumar et al. (2002) Neuropath. Appl. Neurobiol., 28:343-357.
- the total volume of injected AAV solution is for example, between 1 to 5 ⁇ l.
- volumes and delivery rates are appropriately scaled.
- volumes of 150 ⁇ l can be safely injected in the primate brain (Janson et al. (2002) Hum. Gene Then, 13:1391-1412).
- Treatment may consist of a single injection per target site, or may be repeated along the injection tract, if necessary. Multiple injection sites can be used.
- a composition comprising AAV carrying a transgene is administered to another site which can be contralateral or ipsilateral to the first administration site.
- the invention provides a method of delivering a recombinant AAV genome via retrograde axonal transport to the nucleus of a disease-compromised neuron in vivo.
- the cellular pathology exhibited by a neuron is that of a LSD such as listed in Table 1 (see, e.g., Walkley (1998) Brain Pathol., 8:175-193).
- the disease is Niemann-Pick A disease.
- the method of delivering a recombinant AAV genome to the nucleus of a disease-compromised neuron comprises contacting an axonal ending of a disease-compromised neuron with a composition comprising an AAV viral particle comprising the recombinant AAV genome and allowing the viral particle to be endocytosed and retrogradely transported intracellular along the axon to the nucleus of the neuron, wherein the concentration of AAV genomes in the composition is at least: (a) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (*10 12 gp/ml); (b) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (*10 9 tu/ml); or (c) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (*10 10 iu/ml).
- the neuron is a projection neuron and/or the distance from the axonal ending to the nucleus of the neuron is at least 2, 3, 5, 8, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mm.
- the AAV genome is transported along the entire length of the axon, at distances varying depending on the axon length. In humans, these distances may be as much as 1000 mm or greater.
- the invention provides a method of delivering a transgene product to a target cell of the CNS, which is a neuron or a glial cell, in a mammal afflicted with a disorder, for example an LSD as listed in Table 1.
- the method comprises contacting an axonal ending of a neuron with a composition comprising an AAV vector carrying at least a part of a gene encoding a therapeutic transgene product; allowing the viral particles to be endocytosed and retrogradely transported intracellular ⁇ along the axon to the nucleus of the neuron; allowing the transgene product to be expressed and secreted by the neuron; and allowing a second cell to uptake the transgene product, wherein the transgene product thereby alleviates pathology in the second cell.
- the concentration of the AAV vector in the composition is at least: (a) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (*10 12 gp/ml); (b) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (x10 9 tu/ml); or (c) 5, 6, 7, 8, 8.4, 9, 9.3, 10, 15, 20, 25, or 50 (x 10 10 iu/ml).
- lysosomal hydrolases can be secreted by transduced cells and subsequently taken up by another cell via mannose-6-phosphate receptor-mediated endocytosis, the second cell being transduced or non-transduced (Sando et al. (1977) Cell, 12:619-627; Taylor et al. (1997) Nat. Med., 3:771-774; Miranda et al. (2000) Gene Ther., 7:1768-1776; and Jin et al. (2002) J. Clin. Invest, 109:1183-1191).
- AAV of any serotype can be used so long as the vector is capable of undergoing retrograde axonal transport in a disease- compromised brain.
- the serotype of the viral vector used in certain embodiments of the invention is selected from the group consisting from AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, and AAV8 (see, e.g., Gao et al. (2002) PNAS, 99:11854-11859; and Viral Vectors for Gene Therapy: Methods and Protocols, ed. Machida, Humana Press, 2003).
- Other serotype besides those listed herein can be used.
- pseudotyped AAV vectors may also be utilized in the methods described herein.
- AAV vectors are those which contain the genome of one AAV serotype in the capsid of a second AAV serotype; for example, an AAV vector that contains the AAV2 capsid and the AAV1 genome or an AAV vector that contains the AAV5 capsid and the AAV 2 genome.
- AAV5 may be specifically excluded from the methods of the invention utilizing a metalloendopeptidase, e.g., neprilysin, as a therapeutic transgene.
- AAV vectors are derived from single-stranded (ss) DNA parvoviruses that are nonpathogenic for mammals (reviewed in Muzyscka (1992) Curr. Top. Microb. Immunol., 158:97-129). Briefly, AAV-based vectors have the rep and cap viral genes that account for 96% of the viral genome removed, leaving the two flanking 145-basepair (bp) inverted terminal repeats (ITRs), which are used to initiate viral DNA replication, packaging and integration. In the absence of helper virus, wild-type AAV integrates into the human host-cell genome with preferential site-specificity at chromosome 19q 13.3 or it may remain expressed episomally.
- a single AAV particle can accommodate up to 5 kb of ssDNA, therefore leaving about 4.5 kb for a transgene and regulatory elements, which is typically sufficient.
- trans-splicing systems as described, for example, in United States Patent No. 6,544,785, may nearly double this limit.
- AAV is AAV2 or AAV1.
- Adeno-associated virus of many serotypes, especially AAV2 have been extensively studied and characterized as gene therapy vectors. Those skilled in the art will be familiar with the preparation of functional AAV-based gene therapy vectors.
- the vector comprises a transgene operably linked to a promoter.
- the transgene encodes a biologically active molecule, expression of which in the CNS results in at least partial correction of neuropathology.
- the transgene encodes a lysosomal hydrolase.
- the lysosomal hydrolase is ASM.
- the genomic and functional cDNA sequences of human ASM have been published (see, e.g., United States Patent No. 5,773,278 and 6,541,218).
- Other lysosomal hydrolases can be used for appropriate diseases, for example, as listed in Table 1.
- the invention further provides methods of treating Alzheimer's disease in mammals, including humans.
- the transgene encodes a metalloendopeptidase.
- the metalloendopeptidase can be, for example, the amyloid-beta degrading enzyme neprilysin (EC 3.4.24.11 ; sequence accession number, e.g., P08473 (SWISS-PROT)), the insulin-degrading enzyme insulysin (EC 3.4.24.56; sequence accession number, e.g., P14735 (SWISS-PROT)), or thimet oligopeptidase (EC 3.4.24.15; sequence accession number, e.g., P52888 (SWISS-PROT)).
- the level of transgene expression in eukary ⁇ tic cells is largely determined by the transcriptional promoter within the transgene expression cassette. Promoters that show long-term activity and are tissue- and even cell-specific are used in some embodiments. Nonlimiting examples of promoters include, but are not limited to, the cytomegalovirus (CMV) promoter (Kaplitt et al. (1994) Nat. Genet, 8:148-154), CMV/human ⁇ 3-globin promoter (Mandel et al. (1998) J. Neurosci., 18:4271-4284), GFAP promoter (Xu et al.
- CMV cytomegalovirus
- High titer AAV preparations can be produced using techniques known in the art, e.g., as described in United States Patent No. 5,658,776 and Viral Vectors for Gene Therapy: Methods and Protocols, ed. Machida, Humana Press, 2003.
- AAV vector titers were measured according to genome copy number (genome particles per milliliter). Genome particle concentrations were based on Taqman® PCR of the vector DNA as previously reported (Clark et al. (1999) Hum. Gene Then, 10:1031-1039; Veldwijk et al. (2002) MoI. Ther., 6:272-278). Briefly, purified AAV-ASM was treated with capsid digestion buffer (5OmM Tris-HCI pH 8.0, 1.0 mM EDTA, 0.5% SDS, 1.0 mg/ml proteinase K) at 50 0 C for 1 hour to release vector DNA.
- capsid digestion buffer 5OmM Tris-HCI pH 8.0, 1.0 mM EDTA, 0.5% SDS, 1.0 mg/ml proteinase K
- PCR polymerase chain reaction
- primers that anneal to specific sequences in the vector DNA, such as the promoter region, transgene, or the poly A sequence.
- the PCR results were then quantified by a Real-time Taqman® software, such as that provided by the Perkin Elmer-Applied Biosystems (Foster City, CA) Prism 7700 Sequence Detector System.
- Vectors carrying an assayable marker gene such as the ⁇ -galactosidase or green fluorescent protein gene (GFP) can be titered using an infectivity assay.
- Susceptible cells e.g., HeLa, or COS cells
- an assay is performed to determine gene expression such as staining of ⁇ -galactosidase vector-transduced cells with X-gal (5-bromo-4chloro- 3-indolyl- ⁇ -D-galactopyranoside) or fluorescence microscopy for GFP-transduced cells.
- the assay is performed as follows: 4 ⁇ 10 4 HeLa cells are plated in each well of a 24-well culture plate using normal growth media. After attachment, i.e., about 24 hours later, the cells are infected with Ad type 5 at a multiplicity of infection (MOI) of 10 and transduced with serial dilutions of the packaged vector and incubated at 37°C. One to three days later, before extensive cytopathic effects are observed, the appropriate assay is performed on the cells (e.g., X-gal staining or fluorescence microscopy).
- MOI multiplicity of infection
- the cells are fixed in 2% paraformaldehyde, 0.5% glutaraldehyde and stained for ⁇ -galactosidase activity using X-gal. Vector dilutions that give well-separated cells are counted. Each positive cell represents 1 transduction unit (tu) of vector.
- ASMKO mice contain significant NPD pathology in the central nervous system. Identification of homozygous recessive mutants was verified by PCR. Sixteen 10-week old ASMKO mice were anesthetized with isoflurane and mounted on a stereotaxic frame, an incision was made to expose the underlying skull, and a single drill hole was made over one hemisphere of each mouse.
- AAV2-CMV-ASM (Targeted Genetics, Seattle, WA) were injected into the hippocampus at a final stereotaxic coordinate of 2.0 mm rostral of bregma, 1.5 mm right of midline, and 2.0 mm ventral to pial surface. This hippocampal coordinates ensured that the AAV2 vector was exposed to neurons of the dentate gyrus and of the cornu ammonis area 3 (CA3), as well as to axonal endings of projection neurons of the contralateral hippocampus, medial septum and entorhinal cortex. The injections were performed at a rate of 0.2 ⁇ l/minute, and a total of 1.86 ⁇ 10 10 genomic particles were administered into each brain.
- the volume of correction was 30-35 mm 3 or more in the contralateral hippocampus, 5-8 mm 3 or more in the ipsilateral entorhinal cortex, 1-2 mm 3 or more in the contralateral entorhinal cortex, and 2-3 mm 3 or more in the medial septum.
- a single injection of high titer AAV2 vector is sufficient to transfer the ASM gene to structures that innervate the ASMKO affected hippocampus.
- the number of structures positive for AAV2 vector was greater than that demonstrated by a recent study in the normal rat hippocampus, which showed axonal transport only in the entorhinodentate circuit (Kaspar et al. (2002) MoI. Ther., 5:50-56).
- the results described herein demonstrate that axonal transport can occur in projection neurons inflicted with storage pathology, and that this mode of transport results in the clearance of storage pathology in proximal structures and multiple regions distal to the injection site.
- axonal transport is not limited to only those circuits associated with the hippocampus. Retrograde axonal transport occurred in the nigrostriatal ( Figure 3) and in the medullocerebellar ( Figure 4) circuits. This demonstrates that axonal transport of AAV2 in diseased-compromised neurons is a general property of the viral vector.
- AAV1-ASM at the concentrations of 1- 4x10 13 gp/ml and AAV7-ASM at the concentration of 8.4x10 12 gp/ml. While AAV1 did not exhibit detectable retrograde axonal transport, AAV7 did undergo retrograde axonal transport, similar to AAV2, and produced correction of LSD pathology in distal regions (see Figure 5).
- ASMKO mice were anesthetized with isoflurane and mounted on a stereotaxic frame. Bregma was located as a reference point to determine the drilling location for injection into the deep cerebellar nuclei region of the cerebellum. Once located, an incision was made to expose the underlying skull, and a single drill hole was made into the skull without piercing the brain surface. A Hamilton syringe was lowered into the brain via the hole and AAV2-CM ⁇ /-ASM was injected into the deep cerebellar nuclei at a rate of 0.5 microliters per second. Three microliters were injected for a total dose of 1 x 10 10 genome particles. Mice were sacrificed 7 weeks post injection. The brains and spinal cords were evaluated for ASM mRNA expression, ASM protein expression, filipin ' staining, and calbindin staining.
- ASM mRNA and ASM protein were also detected outside the cerebellum. Specifically, the spinal cord was positive for ASM mRNA expression as evidenced by in situ hybridization. The spinal cord was also positive for ASM protein as evidenced by ASM-specific immunofluorescence. These results indicate that the spinal cord was transduced following a distal injection of the AAV vector into the deep cerebellar nuclei. This pattern of transduction was consistent with the topographical organization of the projection neurons that innervate the deep cerebellar nuclei region. These results indicate that the AAV2 vector was taken up by distal spinal cord cells and expressed.
- AD Alzheimer's disease
- a ⁇ amyloid ⁇ -peptide
- Neprilysin is a 97 kD membrane-bound zinc metalloendopeptidase that is the rate-limiting enzyme in the normal degradation of A ⁇ .
- Introduction of neprilysin may decelerate the progression of the disease by removing A ⁇ pools before aggregation. Indeed, neprilysin was shown to degrade oligomeric forms of A ⁇ thereby removing existing plaques in an animal model of AD (Kanemitsu et al. (2003) Neurosci. Lett., 350:113-116).
- Neprilysin knockout mice exhibit high levels of A ⁇ (Iwata et al. (2001) J. Neurosci., 24:991-998.).
- Neprilysin inhibitors such as thiorphan and phosphoramidon, increase A ⁇ levels in mouse brain (Iwata et al. (2000) Nat. Med., 6:143-150). Additionally, decreased neprilysin mRNA levels were found in areas of high amyloid plaque burden in human brains, further demonstrating the link between neprilysin and AD (Yasojima et al. (2001) Neurosci. Lett., 297:97-100).
- the areas of brain most affected by AD are the hippocampus, cortex, cerebellum, striatum and thalamus (see, e.g., Iwata et al. (2001) supra; Yasojima et al. (2001) supra). These are the same areas of the brain that show efficient retrograde axonal transport with AAV.
- AAV can used to deliver therapeutic transgenes to regions of high plaque burden by direct injection and subsequent translocation of virus through brain circuits to our target sites.
- Viral vector-mediated gene transfer of neprilysin was effective in treating mouse models of AD (Marr et al. (2003) J. Neurosci., 23:1992-1996; Marr et al. (2004) J. MoI. Neurosci., 22:5-11; Iwata et al. (2004) J. Neurosci., 24:991-998).
- ASMKO mice Sixty-six male homozygous (-/-) acid sphingomyelinase knockout (ASMKO) mice and sixteen male wild type littermate controls were bred from heterozygote matings (+/-). Mice were genotyped by PCR following the procedure described in GaI et al. (1975) N Engl J Med:293:632-636. Mice from the original colony were backcrossed onto the C57/BI6 strain. Animals were housed under 12:12 hour lightdark cycle and provided with food and water ad libitum. All procedures were performed under a protocol approved by the Institutional Animal Care and Use Committee.
- DCN deep cerebellar nuclei
- Vectors were delivered with a 10 ⁇ l Hamilton syringe mounted on a syringe pump at a rate of 0.5 ⁇ l/minute for a total of 1.86 x 10 10 genome particles per brain. The final injection volume for each vector was 4 ⁇ l.
- Brains from decapitated mice were rapidly removed, snap frozen in liquid nitrogen, dissected into 3 sections (right cerebral hemisphere, left cerebral hemisphere, & cerebellum) homogenized, and analyzed for hASM by ELISA. Brains and spinal cords from perfused mice were processed for human ASM protein expression, cholesterol accumulation as detected by filipin staining, and Purkinje cell survival with calbindin staining on 50 ⁇ m vibratone sections.
- Brains were snap frozen in liquid nitrogen, bisected at midline and then divided into five sections (S1, S2, S3, S4, and S5) using a mouse brain matrix (ASI Instruments, Inc, Ml.) Sections 1-4 were approximately 2 mm apart with S1 being the most rostral and S4 the most caudal. Section 5 contained the cerebellum only. The right hemisphere was used to quantify brain spingomyelin levels and the left hASM levels.
- Human ASM antibodies are human specific and do not cross react with mouse ASM. Coster (Corning, NY) 9018 plates coated (100 ⁇ l/well) with monoclonal recombinant human ASM (rhASM) antibody (2 ⁇ g/ml) diluted in 50 mM sodium carbonate buffer (pH 9.6) were incubated overnight @ 2-8°C. Excess coating antibody was removed and blocking diluent (KPL, Inc., MD) was added for 1 h @ 37°C. Plates were washed with a microplate washer (Molecular Devices, CA) for two cycles.
- rhASM monoclonal recombinant human ASM
- the protein concentration for each sample was determined with a BCA protein assay kit (Pierce Biotechnology, Inc., IL) using bovine serum albumin as standard.
- mice were transcardially perfused with fixative containing 2% paraformaldehyde, 0.03% glutaraldehyde, 0.002% CaCI 2 in 0.1 M sodium acetate buffer at pH 6.5, followed by perfusion with the same fixative at pH 8.5.
- Mouse brains and spinal cords were dissected and post-fixed overnight at 4° C in pH 8.5 fixative without glutaraldehyde.
- the tissues were washed in 0.1 M potassium phosphate buffer, pH 7.4, embedded in 3.5% agar and cut into 50 ⁇ m sagittal sections with a vibratome.
- Brains and spinal cords were vibratome-sectioned sagittally at 50 ⁇ m intervals. Sections were processed for immunofluoresence with primary antibodies against human ASM (1:200). Sections were incubated in 10% donkey serum, 0.3% Triton X-100 in PBS for 1 hour, followed by incubation with biotinylated mouse anti-human ASM in 2% donkey serum, 0.2% Triton X-100 in PBS for 72 hours. After washing, the signal was amplified using a Tyramide Signal Amplification kit (PerkinElmer, Boston MA). Human ASM protein was visualized with a Nikon fluorescent microscope, and images were captured with a SPOT camera and Adobe Photoshop software.
- KPB potassium phosphate buffer
- KPBS potassium phosphate buffered saline
- mice treated with AAV2/1-ASM and had the most widespread (i.e., spread between lobules within the same sagittal section) level of hASM expression whereas mice treated with AAV2/2-ASM had the most restricted level of Human ASM protein expression.
- Human ASM protein expression in mice treated with AAV2/5-ASM, AAV2/7-ASM, and AAV2/8-ASM was intermediate between these two groups.
- Medial - lateral spread between sagittal sections was maximal in mice treated with serotypes 1 & 8 and minimal is mice injected with serotype 2.
- Serotypes 5 & 7 initiated medial -lateral spread patterns intermediate between serotypes 1 and 2.
- Each layer of the cerebellum i.e., molecular, Purkinje and granular
- Purkinje cell transduction was maximal in mice treated with serotypes 1 and 5.
- Mice injected with serotype 7 had the fewest number of transduced Purkinje cells.
- Mice treated with serotype 8 also had few transduced Purkinje cells, but had less ASM expression within the granular layer when compared to serotypes 1 , 2, 5 & 7.
- Purkinje cells transduced with ASM appeared to have a healthy cytostructure.
- mice unilaterally injected with AAV2/1- ASM and AAV2/8-ASM demonstrated a significantly (p ⁇ .0009) longer latency to fall than ASMKO mice injected with AAV2/1- ⁇ gal ( Figure 10).
- Mice injected with serotype AA2/1-ASM were not significantly different from wild type mice.
- Mice injected with AAV2/2-ASM and AAV2/5-ASM showed a trend for a longer latency to fall than ASMKO mice injected with AAV2/1- ⁇ gal; whereas, mice injected with AAV2/7-ASM did not.
- mice injected with AA2/1- ASM demonstrated a significantly (p ⁇ .0001) longer latency to fall than mice injected with AA2/1- ⁇ gal.
- wild type mice performed significantly better than mice injected with AA2/1-ASM ( Figure 10).
- ASMKO mice that received bilateral injection of either AAV2/1-ASM or AAV2/2-ASM performed significantly (p ⁇ .001) better than ASMKO AAV2/1- ⁇ gal treated mice for both accelerating and rocking tests ( Figure 11).
- AAV2/1-ASM bilaterally injected mice performed comparably to wild type mice for both tests.
- AAV generated hASM is functionally active within the ASMKO CNS.
- AAV2/1- ⁇ gal correction of cholesterol storage pathology overlapped with areas that were positive for hASM immunostaining indicating that each serotype vector is capable of generating a functional transgene product.
- correction of abnormal cholesterol metabolism correction also occurred in areas anatomically connected with the injection site, but also in regions that did not stain positively for hASM, suggesting that the level hASM required for correction of cholesterol storage pathology is minimal.
- mice treated with serotypes 1 and 8 demonstrated a marked reduction in cholesterol storage pathology.
- Mice treated with serotypes 2, 5, & 7 also showed a reduction in cholesterol storage pathology, but not to the same extent as mice treated with serotypes 1 & 8.
- sphingomyelin levels which is the primary substrate accumulated in the tissues of mammals with Niemann-Pick disease.
- Brain tissue from mice that received bilateral injections of AAV serotype 1 and 2 were assayed for sphingomyelin (SPM) levels (the tissue homogenization procedure for detection of SPM is not compatible with the detection of hASM.)
- SPM tissue content levels were also significantly reduced in sections 2, 3, and 4 (each section being 2 mm apart from the next) in mice injected with serotype 1 but not in mice injected with serotype 2.
- ASMKO mice that received bilateral intracerebellar injections of AAV serotypes 1 and 2 encoding for hASM showed a significant reduction in sphingomyelin storage within the cerebellum. As observed with cholesterol storage accumulation, a significant reduction in sphingomyelin storage also occurred in regions outside the cerebellum in ASMKO mice bilaterally treated with AAVl
- AAV1 is preferred over serotypes 2, 5, 7, and 8 in its relative ability to initiate enzyme expression, correct storage pathology in the brain, prevent neurodegeneration (by, for example, preventing Purkinje cell death), and improve motor functional outcome.
- the DCN can be exploited as an injection site to maximize enzyme expression throughout the CNS.
- G93A SOD1 SOD1 G93A mutant mouse, referred to here at the SOD1 mouse
- AAV1-GFP AAV serotype 1 encoding for green fluorescent protein
- AAV2-GFP AAV serotype 2 encoding for green fluorescent protein
- mice were injected bilaterally into the DCN with the AAV recombinant vectors using methods similar to those described above.
- the dose was approximately 2.0 e10 gc/ml injected per site.
- Mice were sacrificed about 110 days after birth and their brain and spinal cord were analyzed for GFP staining.
- Green fluorescent protein distribution was observed in the brainstem (see Figure 14) and in the spinal cord regions (see Figure 15) following DCN delivery of AAV encoding for green fluorescent protein (GFP). GFP staining was also observed in the DCN as well as in the olfactory bulbs, cerebral cortex, thalamus, brainstem, cerebellar cortex and spinal cord. All of these areas either receive projections from and/or send projections to the DCN (see Figure 16).
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2607173A CA2607173C (en) | 2005-05-02 | 2006-05-02 | Composition comprising an adeno-associated virus vector having a serotype 1 capsid for use in treating lysosomal storage diseases or alzheimer's disease |
PL19153520T PL3520823T3 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
ES19153520T ES2887076T3 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
AU2006243776A AU2006243776A1 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
EP06759081A EP1879624B1 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
EP19153520.2A EP3520823B1 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
EP16162716.1A EP3058959B1 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
PL06759081T PL1879624T3 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
JP2008510224A JP5829372B2 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
AT06759081T ATE525092T1 (en) | 2005-05-02 | 2006-05-02 | GENE THERAPY FOR NEUROMETABOLIC DISEASES |
PL16162716T PL3058959T3 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
BRPI0611379-6A BRPI0611379A2 (en) | 2005-05-02 | 2006-05-02 | gene therapy for neurometabolic disorders |
IL187078A IL187078A (en) | 2005-05-02 | 2007-11-01 | Compositions comprising aav vector having a serotype 1 capsid and encoding a biologically active molecule for treating a mammal having lysosomal storage disease or alzheimer's disease |
US11/934,325 US10632213B2 (en) | 2005-05-02 | 2007-11-02 | Gene therapy for neurometabolic disorders |
IL239167A IL239167A0 (en) | 2005-05-02 | 2015-06-03 | Compositions comprising aav vector having a serotype 1 capsid and encoding a biologically active molecule for treating a mammal having lysosomal storage disease or alzheimer's disease |
US16/808,206 US11957765B2 (en) | 2005-05-02 | 2020-03-03 | Gene therapy for neurometabolic disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67705705P | 2005-05-02 | 2005-05-02 | |
US60/677,057 | 2005-05-02 | ||
US68580805P | 2005-05-31 | 2005-05-31 | |
US60/685,808 | 2005-05-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/016943 Continuation WO2006119341A2 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for spinal cord disorders |
US11/934,325 Continuation US10632213B2 (en) | 2005-05-02 | 2007-11-02 | Gene therapy for neurometabolic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006119458A1 true WO2006119458A1 (en) | 2006-11-09 |
WO2006119458A9 WO2006119458A9 (en) | 2007-02-15 |
Family
ID=37308324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/017242 WO2006119458A1 (en) | 2005-05-02 | 2006-05-02 | Gene therapy for neurometabolic disorders |
Country Status (13)
Country | Link |
---|---|
US (2) | US10632213B2 (en) |
EP (4) | EP1879624B1 (en) |
JP (3) | JP5829372B2 (en) |
CN (4) | CN107362371A (en) |
AT (1) | ATE525092T1 (en) |
AU (1) | AU2006243776A1 (en) |
BR (1) | BRPI0611379A2 (en) |
CA (2) | CA2998603C (en) |
ES (1) | ES2887076T3 (en) |
IL (2) | IL187078A (en) |
PL (4) | PL3520823T3 (en) |
PT (4) | PT3520823T (en) |
WO (1) | WO2006119458A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2158322A4 (en) * | 2007-06-06 | 2011-06-01 | Genzyme Corp | Gene therapy for lysosomal storage diseases |
WO2012078209A1 (en) | 2010-12-06 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microrna-483 |
EP2687609A2 (en) | 2008-11-10 | 2014-01-22 | The United States of America As Represented by the Secretary Department of Health and Human Services | Method for treating solid tumor |
US9415119B2 (en) | 2009-05-02 | 2016-08-16 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US11103596B2 (en) | 2015-05-11 | 2021-08-31 | Ucl Business Plc | Fabry disease gene therapy |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006242129A1 (en) * | 2005-05-02 | 2006-11-09 | Genzyme Corporation | Gene therapy for spinal cord disorders |
PT3520823T (en) | 2005-05-02 | 2021-09-16 | Genzyme Corp | Gene therapy for neurometabolic disorders |
PT2029742T (en) | 2006-06-07 | 2016-09-09 | Genzyme Corp | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
WO2012145646A1 (en) * | 2011-04-20 | 2012-10-26 | Miguel Sena-Esteves | Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
JP6401871B2 (en) | 2014-11-05 | 2018-10-10 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | AADC polynucleotide for the treatment of Parkinson's disease |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
EP3218484A4 (en) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
US11319555B2 (en) | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
EP3273982B1 (en) | 2015-03-26 | 2020-11-18 | Suzhou Auzone Biological Technology Co., Ltd | Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75 |
US11027024B2 (en) | 2015-05-29 | 2021-06-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017201258A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
EP3458588A4 (en) | 2016-05-18 | 2020-01-15 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
JOP20190200A1 (en) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | Compositions useful in treatment of spinal muscular atrophy |
WO2018204803A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
JP2020518258A (en) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Amyotrophic lateral sclerosis (ALS) treatment composition and method |
NZ760232A (en) | 2017-06-07 | 2023-05-26 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
US20040258666A1 (en) * | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8303626D0 (en) | 1983-06-23 | 1983-06-23 | Kabigen Ab | A RECOMBINANT PLASMID AND A TRANSFORMANT MICROORGANISM, A POLYDOXYREBONUCLEOTIDE SEGMENT, A PROCESS FOR PRODUCING A BIOLOGICALLY ACTIVE PROTEIN, AND THE PROTEIN THUS PRODUCED |
US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
ES2249761T3 (en) | 1993-06-24 | 2006-04-01 | Advec Inc. | ADENOVIRUS VECTORS FOR GENE THERAPY. |
DK0797676T3 (en) | 1993-10-25 | 2006-04-18 | Canji Inc | Recombinant adenoviral vector and methods for its use |
AU688428B2 (en) | 1993-11-09 | 1998-03-12 | Johns Hopkins University, The | Generation of high titers of recombinant AAV vectors |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
CA2187626C (en) | 1994-04-13 | 2009-11-03 | Michael G. Kaplitt | Aav-mediated delivery of dna to cells of the nervous system |
WO1997039789A1 (en) | 1996-04-22 | 1997-10-30 | Medtronic, Inc. | Two-stage angled venous cannula |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
WO2001036603A2 (en) * | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
JP2004516016A (en) | 2000-09-18 | 2004-06-03 | ジェンザイム・コーポレイション | Expression vector containing hybrid ubiquitin promoter |
US20030050273A1 (en) * | 2001-08-29 | 2003-03-13 | Keiya Ozawa | Compositions and methods for treating neurodegenerative diseases |
US7232670B2 (en) * | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
EP3517134B1 (en) | 2001-12-17 | 2024-01-17 | The Trustees of the University of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same and uses therefor |
US6998118B2 (en) | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
CA2471812C (en) | 2001-12-21 | 2012-09-04 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery to motor neurons |
WO2003100031A2 (en) * | 2002-05-20 | 2003-12-04 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
WO2004098648A1 (en) * | 2003-05-01 | 2004-11-18 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
US7740168B2 (en) | 2003-08-18 | 2010-06-22 | Visa U.S.A. Inc. | Method and system for generating a dynamic verification value |
US20070275449A1 (en) | 2003-10-15 | 2007-11-29 | Vector Gene Technology Company Ltd. | Method for Large-Scale Production, Isolation, Purification and the Uses of Multi-Type Recombinant Adeno-Associated Virus Vectors |
EP1716870A1 (en) | 2005-04-29 | 2006-11-02 | Bracco Imaging S.p.A. | MRI contrast agents endowed with concentration independent responsiveness |
AU2006242129A1 (en) | 2005-05-02 | 2006-11-09 | Genzyme Corporation | Gene therapy for spinal cord disorders |
PT3520823T (en) | 2005-05-02 | 2021-09-16 | Genzyme Corp | Gene therapy for neurometabolic disorders |
PL1986661T3 (en) | 2006-02-08 | 2019-02-28 | Genzyme Corporation | Gene therapy for niemann-pick disease type a |
MX365242B (en) | 2011-05-16 | 2019-05-28 | Genzyme Corp | Use of cxcr4 antagonists. |
TWI821227B (en) | 2017-12-22 | 2023-11-11 | 美商健臻公司 | Biomarkers of methotrexate-induced immune tolerance |
-
2006
- 2006-05-02 PT PT19153520T patent/PT3520823T/en unknown
- 2006-05-02 CA CA2998603A patent/CA2998603C/en active Active
- 2006-05-02 PL PL19153520T patent/PL3520823T3/en unknown
- 2006-05-02 ES ES19153520T patent/ES2887076T3/en active Active
- 2006-05-02 CN CN201710506914.9A patent/CN107362371A/en active Pending
- 2006-05-02 EP EP06759081A patent/EP1879624B1/en active Active
- 2006-05-02 EP EP11169633.2A patent/EP2420256B1/en active Active
- 2006-05-02 PT PT06759081T patent/PT1879624E/en unknown
- 2006-05-02 PL PL16162716T patent/PL3058959T3/en unknown
- 2006-05-02 PT PT111696332T patent/PT2420256T/en unknown
- 2006-05-02 CN CNA2006800237754A patent/CN101212988A/en active Pending
- 2006-05-02 CN CN201611031204.7A patent/CN107007842A/en active Pending
- 2006-05-02 WO PCT/US2006/017242 patent/WO2006119458A1/en active Application Filing
- 2006-05-02 PL PL06759081T patent/PL1879624T3/en unknown
- 2006-05-02 PL PL11169633.2T patent/PL2420256T3/en unknown
- 2006-05-02 BR BRPI0611379-6A patent/BRPI0611379A2/en not_active Application Discontinuation
- 2006-05-02 JP JP2008510224A patent/JP5829372B2/en active Active
- 2006-05-02 EP EP16162716.1A patent/EP3058959B1/en active Active
- 2006-05-02 AU AU2006243776A patent/AU2006243776A1/en not_active Abandoned
- 2006-05-02 PT PT16162716T patent/PT3058959T/en unknown
- 2006-05-02 CN CN201410483749.6A patent/CN104306986A/en active Pending
- 2006-05-02 EP EP19153520.2A patent/EP3520823B1/en active Active
- 2006-05-02 AT AT06759081T patent/ATE525092T1/en not_active IP Right Cessation
- 2006-05-02 CA CA2607173A patent/CA2607173C/en active Active
-
2007
- 2007-11-01 IL IL187078A patent/IL187078A/en not_active IP Right Cessation
- 2007-11-02 US US11/934,325 patent/US10632213B2/en active Active
-
2013
- 2013-09-27 JP JP2013201138A patent/JP2014037418A/en active Pending
-
2015
- 2015-06-03 IL IL239167A patent/IL239167A0/en unknown
- 2015-10-02 JP JP2015197051A patent/JP6338560B2/en active Active
-
2020
- 2020-03-03 US US16/808,206 patent/US11957765B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
US20040258666A1 (en) * | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
Non-Patent Citations (3)
Title |
---|
BOSCH A. ET AL.: "Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors", MOL. THER., vol. 1, no. 1, January 2000 (2000-01-01), pages 63 - 70, XP008123629 * |
DATTO J. ET AL.: "Distribution of AAV-1 GFP with respect to time, distance traveled, and expression following injection to the midbrain", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER, 2002, XP008072025 * |
LIU Y. ET AL.: "High level of transduction of mammalian brain by adeno-associated type 1 virus vector", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER, 2002, pages 1, XP008123633 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2158322A4 (en) * | 2007-06-06 | 2011-06-01 | Genzyme Corp | Gene therapy for lysosomal storage diseases |
US8796236B2 (en) | 2007-06-06 | 2014-08-05 | Genzyme Corporation | Gene therapy for lysosomal storage diseases |
EP3252161A1 (en) * | 2007-06-06 | 2017-12-06 | Genzyme Corporation | Gene therapy for lysosomal storage diseases |
EP2687609A2 (en) | 2008-11-10 | 2014-01-22 | The United States of America As Represented by the Secretary Department of Health and Human Services | Method for treating solid tumor |
US9415119B2 (en) | 2009-05-02 | 2016-08-16 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US10369193B2 (en) | 2009-05-02 | 2019-08-06 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US11911440B2 (en) | 2009-05-02 | 2024-02-27 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
WO2012078209A1 (en) | 2010-12-06 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microrna-483 |
US11103596B2 (en) | 2015-05-11 | 2021-08-31 | Ucl Business Plc | Fabry disease gene therapy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11957765B2 (en) | Gene therapy for neurometabolic disorders | |
JP6312771B2 (en) | Gene therapy for neurometabolic disorders | |
US10913956B2 (en) | Gene therapy for neurometabolic disorders | |
EP1879623B1 (en) | Gene therapy for spinal cord disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680023775.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006243776 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2607173 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/013733 Country of ref document: MX Ref document number: 187078 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2008510224 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006243776 Country of ref document: AU Date of ref document: 20060502 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4537/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006759081 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0611379 Country of ref document: BR Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 239167 Country of ref document: IL |